Clinical Scorecard: A Case Report on Severe 3M Syndrome Induced by Immune Checkpoint Inhibitors

At a Glance

Key Highlights

• 3M syndrome is characterized by the overlap of myocarditis, myositis, and myasthenia gravis.
• Early symptoms include ptosis, facial weakness, and dizziness, often leading to delayed diagnosis.
• Mortality rates for 3M syndrome can be as high as 40-60%.
• Proactive monitoring and immediate immunosuppressive treatment are essential.
• The case emphasizes the need for structured monitoring in patients receiving ICIs.

Guideline-Based Recommendations

Diagnosis

• Monitor for early neuromuscular symptoms in patients receiving ICIs.
• Utilize cardiac biomarkers and echocardiography for diagnosis of myocarditis.

Management

• Initiate high-dose methylprednisolone and IVIG for treatment of 3M syndrome.

Monitoring & Follow-up

• Implement routine surveillance for endocrine and neuromuscular adverse events.

Risks

• Increased risk of severe adverse events with the combination of myocarditis, myositis, and myasthenia gravis.

Patient & Prescribing Data

65-year-old female with FIGO stage IIIA cervical squamous cell carcinoma.

Received anti-PD-1 monoclonal antibody (Enlarzumab) combined with chemoradiotherapy.

Clinical Best Practices

• Establish a systematic approach for monitoring patients on ICIs.
• Educate patients and caregivers about early signs of irAEs.

Related Resources & Content

• Immune Checkpoint Inhibitors and Myocarditis
• Management of ICI-related Myocarditis